KF 58333

Drug Profile

KF 58333

Latest Information Update: 26 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko
  • Class Antineoplastics; Oximes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 26 Oct 2006 Discontinued - Preclinical for Chronic myeloid leukaemia in Japan (unspecified route)
  • 23 Aug 2000 A preclinical study has been added to the pharmacodynamics section
  • 25 Jul 2000 Preclinical development for Chronic myeloid leukaemia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top